BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,843,928 | -47.8% | 56,470 | -37.4% | 0.00% | -50.0% |
| Q2 2023 | $7,362,922 | +16.0% | 90,199 | +5.5% | 0.00% | 0.0% |
| Q1 2023 | $6,345,463 | -56.2% | 85,529 | -51.1% | 0.00% | -50.0% |
| Q4 2022 | $14,483,528 | +27.5% | 174,753 | +336.8% | 0.00% | 0.0% |
| Q3 2022 | $11,362,000 | -24.4% | 40,009 | -7.7% | 0.00% | -20.0% |
| Q2 2022 | $15,027,000 | -63.6% | 43,352 | -54.5% | 0.01% | -54.5% |
| Q1 2022 | $41,288,000 | +36.5% | 95,344 | +63.1% | 0.01% | +37.5% |
| Q4 2021 | $30,248,000 | -75.9% | 58,468 | -77.4% | 0.01% | -71.4% |
| Q3 2021 | $125,501,000 | +30.4% | 258,993 | +21.2% | 0.03% | +33.3% |
| Q2 2021 | $96,213,000 | +5.5% | 213,685 | -10.5% | 0.02% | 0.0% |
| Q1 2021 | $91,182,000 | +23.4% | 238,741 | +2.6% | 0.02% | +16.7% |
| Q4 2020 | $73,866,000 | +46.6% | 232,611 | +14.4% | 0.02% | +28.6% |
| Q3 2020 | $50,374,000 | +288.0% | 203,342 | +313.6% | 0.01% | +250.0% |
| Q2 2020 | $12,982,000 | +27.7% | 49,160 | -8.3% | 0.00% | 0.0% |
| Q1 2020 | $10,168,000 | -25.4% | 53,624 | -13.7% | 0.00% | 0.0% |
| Q4 2019 | $13,632,000 | +18.9% | 62,107 | +6.0% | 0.00% | +33.3% |
| Q3 2019 | $11,467,000 | +0.5% | 58,604 | +7.0% | 0.00% | 0.0% |
| Q2 2019 | $11,414,000 | +8.2% | 54,750 | +3.0% | 0.00% | 0.0% |
| Q1 2019 | $10,549,000 | +44.2% | 53,133 | +5.1% | 0.00% | +50.0% |
| Q4 2018 | $7,316,000 | -38.1% | 50,555 | -12.7% | 0.00% | -33.3% |
| Q3 2018 | $11,826,000 | +50.7% | 57,942 | +9.2% | 0.00% | +50.0% |
| Q2 2018 | $7,848,000 | -2.8% | 53,039 | -0.8% | 0.00% | 0.0% |
| Q1 2018 | $8,071,000 | +20.8% | 53,441 | +3.7% | 0.00% | 0.0% |
| Q4 2017 | $6,679,000 | -2.0% | 51,559 | -8.5% | 0.00% | 0.0% |
| Q3 2017 | $6,813,000 | +16.8% | 56,356 | +13.5% | 0.00% | 0.0% |
| Q2 2017 | $5,834,000 | +24.3% | 49,657 | +7.5% | 0.00% | 0.0% |
| Q1 2017 | $4,695,000 | +16.4% | 46,182 | +17.7% | 0.00% | +100.0% |
| Q4 2016 | $4,034,000 | -7.6% | 39,227 | -1.6% | 0.00% | -50.0% |
| Q3 2016 | $4,367,000 | -1.2% | 39,875 | +1.8% | 0.00% | 0.0% |
| Q2 2016 | $4,418,000 | +21.7% | 39,172 | +2.0% | 0.00% | +100.0% |
| Q1 2016 | $3,629,000 | -28.6% | 38,391 | -32.0% | 0.00% | -50.0% |
| Q4 2015 | $5,084,000 | +35.4% | 56,481 | +39.1% | 0.00% | 0.0% |
| Q3 2015 | $3,755,000 | -10.7% | 40,610 | -4.9% | 0.00% | 0.0% |
| Q2 2015 | $4,204,000 | -46.3% | 42,688 | -45.3% | 0.00% | 0.0% |
| Q1 2015 | $7,834,000 | +135.5% | 78,108 | +117.0% | 0.00% | +100.0% |
| Q4 2014 | $3,326,000 | – | 36,001 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |